Halsa Pharmaceuticals Announces ZAG Demonstrates Weight Loss, Rise in Temperature and Reduction of Diabetes Symptoms in Preclinical Studies at Obesity

"Suggests Increase in Energy Expenditure and Potential as Treatment for Obesity and Type 2 Diabetes

HOUSTON--(Business Wire)--

Houston-based Halsa Pharmaceuticals, Inc., a biotechnology company developing therapeutics for the treatment of obesity, diabetes, cachexia and other metabolic diseases, today announced results from preclinical studies demonstrating that recombinant human Zinc-α2-glycoprotein (ZAG) induced a progressive loss of body weight in mice of 3.5g in five days, together with a rise in temperature of 0.4°C, suggesting an increase in energy expenditure. In addition, ZAG produced a normalization of the diabetic glucose tolerance curve after three days of treatment, suggesting that ZAG may have a therapeutic application in the treatment of obesity and Type 2 diabetes. The results from this study were presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, one of the largest scientific conferences in the field of obesity, being held in Washington, D.C. October 24-28...

Summary Results:

* ZAG induced a progressive loss of body weight in mice of 3.5g in five days, together with a rise in temperature of 0.4°C."